A Look At Celcuity (CELC) Valuation After Charles Romp Joins The Board And Gedatolisib Progress

2026-03-12 02:21:06

Celcuity (CELC) recently appointed Charles R. Romp to its Board of Directors, drawing attention to its oncology pipeline, specifically Gedatolisib. Despite significant share price swings and a current trading price below analyst targets, the company’s valuation presents a mixed picture. A DCF model suggests Celcuity is significantly undervalued at $549.38 per share compared to its current market price of $107.38, primarily based on the potential success of Gedatolisib, but its high P/B ratio of 42.5x indicates investors are paying a steep premium for net assets.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.